Sorrento Therapeutics Inc. announced that it has acquired the exclusive rights to Cynviloq in Australia, Canada and Mexico from Samyang Biopharmaceuticals, a South Korean corporation. Sorrento has the exclusive rights to Samyang's Cynviloq (marketed as Genexol-PM in South Korea and other countries) in the US and the 27 countries of the EU. According to the company, Cynviloq (IG-001; a paclitaxel-loaded micellar diblock copolymer) is a next-generation branded paclitaxel formulation for the potential treatment of metastatic breast cancer, non-small cell lung cancer, pancreatic cancer and other solid tumors.